^
Association details:
| Biomarker: | TMB-H + PIK3CA mutation |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
873P - Identification of PIK3CA mutation as a novel predictor of efficacious immunotherapy in head and neck cancer
Published date:
10/16/2023
Excerpt:
The TMB level of PIK3CA-Mut patients was higher than PIK3CA-WT patients in both MSKCC (Median [IQR]: 7.02[4.92-10.53] vs. 4.91[2.63-7.90], P=0.006) and TCGA (Median [IQR]: 3.03[1.98-4.42] vs. 2.62[1.66-3.92], P=0.045) cohort….PIK3CA-Mut is associated with higher TMB in ICI-treated HNSC patients. Survival analysis shows PIK3CA-Mut have a good link with longer OS after immunotherapy. These findings indicate that PIK3CA mutation may serve as a potential predictive biomarker for ICIs in HNSC.
